Deinove (ALDEI)

Business description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Stock data

Market cap.€18.4m
Last close€1.69
High / Low (52 weeks)€2.4 / €1.7
Stock market listingEG
Forecast net debt (€m)5.1
Forecast gearing ratio (%)2716
SectorAlternative Energy

Price performance

Relative *(1.3)(19.9)(28.1)

* % Relative to local index

Other companies in sector Show

Company news

Deinove SA (ALDEI) Increases 2.38% on Nov 21

Tue, 21 Nov 2017 12:45:00 GMT

DEINOVE and ARBIOM join forces to develop a "carbon-free" chemical industry

Mon, 14 Mar 2016 18:00:00 GMT

Deinove SA (ALDEI) Dips -3.31% on Oct 31

Tue, 31 Oct 2017 16:30:00 GMT

Deinove SA (ALDEI) Declines -1.12% on Nov 16

Thu, 16 Nov 2017 14:26:15 GMT

The Digest's 2015 6-Minute Country Guide to France's Advanced Bioeconomy

Wed, 16 Sep 2015 08:01:35 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 0.5 (7.3) (7.3) (66.8) N/A N/A
2016A 0.8 (7.0) (6.9) (64.6) N/A N/A
2017E 0.8 (7.9) (8.6) (65.7) N/A N/A
2018E 2.9 (5.8) (6.8) (44.1) N/A N/A

Last updated on 02/11/2017

Investment summary

Deinove's H117 results were broadly in line with our FY17 forecasts at the net profit level, with a net loss of €3.3m for the half-year (€3.4m loss H116). Net cash was €6.6m at H117 (FY16: €9.3m). In H117, Deinove also strengthened its management team, acquired the minorities of Deinobiotics and issued two patent applications for an antibiotic molecule. A partnership in cosmetics was signed with Greentech and the COLOR2B project passed the second phase. Since the period end, the carotenoids programme has entered the industrialisation phase and Deinove also announced that its Antibiotics against Resistant Infectious Germs (AGIR) project, carried out jointly with the Charles Viollette Institute, had been selected by the Investments for the Future programme, entitling the project to funding of €14.6m in 2017-22.

Last updated on 02/11/2017

Industry outlook

Environmentalism will underpin growth in green chemistry, and the growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 02/11/2017

Key management

Dr Philippe Pouletty, Chairman
Emmanuel Petiot, CEO
Julien Coste, CFO

Company address

22 rue Leon Jouhaux
75010 Paris
01 42 03 27 37
View website